NorLevo leads latest batch of Japanese approvals
This article was originally published in Scrip
Sosei's emergency contraceptive NorLevo has been approved in Japan, for use within 72 hours of unprotected intercourse or known or suspected contraceptive failure.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.